Randy Scott talks about the diagnostic odyssey, the travel from doctor to doctor to nail down a person's diagnosis with this or that disease. His Invitae Corp., one of a growing pack of genetic testing companies, wants to reroute the trip.
In the latest episode of our BioFlash podcast, we talk to Scott, the CEO of Invitae (NASDAQ: NVTA) about his San Francisco-based company's goal to bring comprehensive genetic testing mainstream as the cost of genetic sequencing continues to sink lower.
HEAR MORE
…
Randy Scott talks about the diagnostic odyssey, the travel from doctor to doctor to nail down a person's diagnosis with this or that disease. His Invitae Corp., one of a growing pack of genetic testing companies, wants to reroute the trip.
In the latest episode of our BioFlash podcast, we talk to Scott, the CEO of Invitae (NASDAQ: NVTA) about his San Francisco-based company's goal to bring comprehensive genetic testing mainstream as the cost of genetic sequencing continues to sink lower.
HEAR MORE
…